Clinical trial
Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus…
NCT00210353 · International Extranodal Lymphoma Study Group (IELSG), Other · Completed
Key facts
| NCT number | NCT00210353 |
|---|---|
| Title | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma |
| Official title | Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) |
| Lead sponsor | International Extranodal Lymphoma Study Group (IELSG), Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Mucosa-Associated Lymphoid Tissue |
| Intervention type | Drug |
| Interventions | chlorambucil (drug), rituximab+chlorambucil, rituximab |
| Enrollment | 454 |
| Start date | Jan 1, 2003 |
| Primary completion | Apr 1, 2015 |
| Completion | Feb 17, 2016 |
| First posted | Sep 21, 2005 |
| Last update posted | Jun 6, 2019 |
| Countries | Belgium, France, Italy, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: